Navigation Links
Appeal Court's Direction on Claim Construction Is Strategically Important for Butamax's Case Against Gevo Scheduled for April 2013
Date:11/19/2012

WILMINGTON, Del., Nov. 19, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, commented on the decision by the Federal Circuit.  While the Federal Circuit affirmed the District Court's preliminary injunction decision, Butamax is pleased with the Federal Circuit's direction on claim construction.  The District Court's narrow interpretation of Butamax's patent was not endorsed and, in the words of the Federal Circuit:

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

"…this court's affirmance should not be read to endorse the trial court's very questionable construction of the claim term "acetohydroxy acid isomeroreductase" – that is "as an enzyme that is solely NADPH dependent.  The trial court should reconsider its construction when it holds a Markman hearing."

Gevo had argued that it did not infringe Butamax's patent because of this narrowed scope of the KARI enzyme.  Butamax is confident that, with a revised claim construction, it will succeed in its infringement arguments against Gevo.  The Federal Circuit also commented that Butamax did not demonstrate that Gevo's arguments on validity lacked substantial merit as required for the grant of a preliminary injunction. Butamax will address these issues at the April 2013 trial, which will also cover the full scope of the '188 and '889 patents.

About Butamax
Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Pam Schools 910-777-7119
pamela.schools@butamax.com

 


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
2. Sequenom, Inc. Files Notice Of Appeal Of Preliminary Injunction Denial
3. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
4. Why Medicare Carrier Proposes Major Changes in the Handling of Code Stacked Molecular Test Claims is Topic of December 20 Audio Conference
5. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
8. The Energy Scientific World Acclaims the Global Energy Prize 2012 Laureates
9. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
10. MetaStat, Inc. Announces Allowance of Patent Claims
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... 17, 2017 , ... Whitehouse Laboratories is excited to announce ... full series of ISO 80369 standard test procedures. The ISO 80369 series of ... delivery systems. With this recent expansion, Whitehouse Labs becomes one of the only ...
(Date:7/17/2017)... Doylestown, Pa. (PRWEB) , ... ... ... leading provider of technology-enabled clinical trial solutions, today announced safety software company ... channel within the eHealth Solutions business segment to advance technology innovation across ...
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) are ... overlapping clinical features. The advancement of targeted next-generation sequencing (NGS) has been instrumental ... testing. , However, designing a custom panel for disease research requires hours ...
(Date:7/17/2017)... ... July 17, 2017 , ... Co-Diagnostics, Inc. (NASDAQ: CODX) ... both to manufacture and sell reagents used for diagnostic tests, has completed its ... in Sandy, Utah, Co-Diagnostics’ intellectual property and technologies are protected by five granted ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):